Alvogen is first to market and has received final approval for the generic equivalent to Tamiflu® (oseltamivir phosphate) 6 mg/ml powder for oral suspension in the United States. In December 2016, Alvogen launched the first generic equivalent to Tamiflu® (oseltamivir phosphate) capsules in the United States.
Annual sales for Oseltamivir suspension amount to $312 million in the U.S. market, based on IMS Midas data.
Alvogen currently has 75 products in development and pending FDA approval for the U.S. market. Annual brand sales for filed products and those under development have current brand sales exceeding $25 billion, according to IMS Health (2015).
*Tamiflu is a registered trademark of Hoffman La-Roche Inc. Corporation.